Commentary: A case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability

Shrikanta Chattopadhyay, Roni Tamari, Sang H. Min, Rongbao Zhao, Eugenia Tsai, I. David Goldman

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Pemetrexed is a novel antifolate recently approved for the treatment of pleural mesothelioma and non-small cell lung cancer. In clinical regimens, pemetrexed is administered in conjunction with folic acid to minimize toxicity. However, excessive folate supplementation may also diminish the activity of this agent. The current study demonstrates, in several human solid tumor cell lines, that when extracellular 5-formyltetrahydrofolate levels are increased in vitro, within the range of normal human blood levels, there is a substantial decrease in pemetrexed activity upon continuous exposure to the drug. This was accompanied by a comparable lower level of trimetrexate activity consistent with an expansion of tumor cell folate pools. Likewise, when cells were exposed to pemetrexed with a schedule that simulates in vivo pharmacokinetics, there was markedly less cell killing with higher extracellular folate levels. Data are provided to indicate that 5-formyltetrahydrofolate is an acceptable surrogate for 5-methyltetrahydrofolate, the major blood folate, for this type of in vitro study. These observations and other reports suggest that, in view of the rise in serum folate and fall in serum homocysteine that has accompanied folic acid supplementation of food in the U.S., the addition of folic acid to regimens with pemetrexed should be limited to the lowest recommended level that provides optimal protection from pemetrexed toxicity.

Original languageEnglish (US)
Pages (from-to)808-815
Number of pages8
JournalOncologist
Volume12
Issue number7
DOIs
StatePublished - Jul 2007

Fingerprint

Pemetrexed
Folic Acid
Pharmaceutical Preparations
Leucovorin
Trimetrexate
Folic Acid Antagonists
Mesothelioma
Homocysteine
Dietary Supplements
Tumor Cell Line
Serum
Non-Small Cell Lung Carcinoma
Appointments and Schedules
Reference Values
Pharmacokinetics

Keywords

  • Antifolates
  • Folate pools
  • Folic acid
  • Pemetrexed

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Commentary : A case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. / Chattopadhyay, Shrikanta; Tamari, Roni; Min, Sang H.; Zhao, Rongbao; Tsai, Eugenia; Goldman, I. David.

In: Oncologist, Vol. 12, No. 7, 07.2007, p. 808-815.

Research output: Contribution to journalArticle

@article{0dafa12b39dc4b3ba90e13a48a33542b,
title = "Commentary: A case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability",
abstract = "Pemetrexed is a novel antifolate recently approved for the treatment of pleural mesothelioma and non-small cell lung cancer. In clinical regimens, pemetrexed is administered in conjunction with folic acid to minimize toxicity. However, excessive folate supplementation may also diminish the activity of this agent. The current study demonstrates, in several human solid tumor cell lines, that when extracellular 5-formyltetrahydrofolate levels are increased in vitro, within the range of normal human blood levels, there is a substantial decrease in pemetrexed activity upon continuous exposure to the drug. This was accompanied by a comparable lower level of trimetrexate activity consistent with an expansion of tumor cell folate pools. Likewise, when cells were exposed to pemetrexed with a schedule that simulates in vivo pharmacokinetics, there was markedly less cell killing with higher extracellular folate levels. Data are provided to indicate that 5-formyltetrahydrofolate is an acceptable surrogate for 5-methyltetrahydrofolate, the major blood folate, for this type of in vitro study. These observations and other reports suggest that, in view of the rise in serum folate and fall in serum homocysteine that has accompanied folic acid supplementation of food in the U.S., the addition of folic acid to regimens with pemetrexed should be limited to the lowest recommended level that provides optimal protection from pemetrexed toxicity.",
keywords = "Antifolates, Folate pools, Folic acid, Pemetrexed",
author = "Shrikanta Chattopadhyay and Roni Tamari and Min, {Sang H.} and Rongbao Zhao and Eugenia Tsai and Goldman, {I. David}",
year = "2007",
month = "7",
doi = "10.1634/theoncologist.12-7-808",
language = "English (US)",
volume = "12",
pages = "808--815",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "7",

}

TY - JOUR

T1 - Commentary

T2 - A case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability

AU - Chattopadhyay, Shrikanta

AU - Tamari, Roni

AU - Min, Sang H.

AU - Zhao, Rongbao

AU - Tsai, Eugenia

AU - Goldman, I. David

PY - 2007/7

Y1 - 2007/7

N2 - Pemetrexed is a novel antifolate recently approved for the treatment of pleural mesothelioma and non-small cell lung cancer. In clinical regimens, pemetrexed is administered in conjunction with folic acid to minimize toxicity. However, excessive folate supplementation may also diminish the activity of this agent. The current study demonstrates, in several human solid tumor cell lines, that when extracellular 5-formyltetrahydrofolate levels are increased in vitro, within the range of normal human blood levels, there is a substantial decrease in pemetrexed activity upon continuous exposure to the drug. This was accompanied by a comparable lower level of trimetrexate activity consistent with an expansion of tumor cell folate pools. Likewise, when cells were exposed to pemetrexed with a schedule that simulates in vivo pharmacokinetics, there was markedly less cell killing with higher extracellular folate levels. Data are provided to indicate that 5-formyltetrahydrofolate is an acceptable surrogate for 5-methyltetrahydrofolate, the major blood folate, for this type of in vitro study. These observations and other reports suggest that, in view of the rise in serum folate and fall in serum homocysteine that has accompanied folic acid supplementation of food in the U.S., the addition of folic acid to regimens with pemetrexed should be limited to the lowest recommended level that provides optimal protection from pemetrexed toxicity.

AB - Pemetrexed is a novel antifolate recently approved for the treatment of pleural mesothelioma and non-small cell lung cancer. In clinical regimens, pemetrexed is administered in conjunction with folic acid to minimize toxicity. However, excessive folate supplementation may also diminish the activity of this agent. The current study demonstrates, in several human solid tumor cell lines, that when extracellular 5-formyltetrahydrofolate levels are increased in vitro, within the range of normal human blood levels, there is a substantial decrease in pemetrexed activity upon continuous exposure to the drug. This was accompanied by a comparable lower level of trimetrexate activity consistent with an expansion of tumor cell folate pools. Likewise, when cells were exposed to pemetrexed with a schedule that simulates in vivo pharmacokinetics, there was markedly less cell killing with higher extracellular folate levels. Data are provided to indicate that 5-formyltetrahydrofolate is an acceptable surrogate for 5-methyltetrahydrofolate, the major blood folate, for this type of in vitro study. These observations and other reports suggest that, in view of the rise in serum folate and fall in serum homocysteine that has accompanied folic acid supplementation of food in the U.S., the addition of folic acid to regimens with pemetrexed should be limited to the lowest recommended level that provides optimal protection from pemetrexed toxicity.

KW - Antifolates

KW - Folate pools

KW - Folic acid

KW - Pemetrexed

UR - http://www.scopus.com/inward/record.url?scp=34548207202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548207202&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.12-7-808

DO - 10.1634/theoncologist.12-7-808

M3 - Article

C2 - 17673612

AN - SCOPUS:34548207202

VL - 12

SP - 808

EP - 815

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 7

ER -